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Feature Section: Carcinoma of the Prostate 
Adenocarcinoma of the Prostate: Overview H 
This section ofthe Journal features an update on current top-ics in the diagnosis and management of prostate cancer and 
follows and builds upon a similar section of papers published in 
the Journal three years ago (Volume 37, Number 1, 1989). 
National attention has focused recently on prostatic adeno-
carcinoma, and the demographics of this disease are increas-
ingly recognized and discussed. Adenocarcinoma of the pros-
tate is now the most common visceral cancer of males in the 
United States. It is estimated that 132,000 new cases of prostate 
cancer will be diagnosed and that 34,000 deaths wilt occur from 
this disease in 1992. American black males have an incidence 
and mortality 50% higher than that for white males and a death 
rate that is the highest in the world. Burks and Littleton (pp. 89-
92) review the current literature in the epidemiology of prostate 
cancer in black men, examining a variety of possible causative 
factors. 
Dr, Shetty and I attempt to put into perspective the use of 
prostate-specific antigen (PSA) in screening, staging, and moni-
toring carcinoma of the prostate (pp, 93-98), Prostate-specific 
antigen density (PSAD), defined as serum PSA divided by pros-
tate gland volume, may be a more useful predictor of prostate 
cancer than semm PSA alone. The roles of digital rectal exami-
nation (DRE), PSA, PSAD, and transrectal ultrasound (TRUS) 
are discussed. The utilization of these techniques in "screening" 
is assessed, recognizing that patients have a much greater risk of 
developing prostate cancer than dying of it and that earty diag-
nosis must be tempered by an understanding of the natural his-
tory of the disease. 
Peters-Gee, in her excellent update on the role of ploidy in 
prostate carcinoma (pp. 99-102), discusses DNA quantitation as 
a prognostic determinant that may give insight into the biologi-
cal behavior of the neoplasm in individual patients. This may 
aid in the selection of those patients whose neoplasm should be 
treated aggressively, versus patients with small, differentiated, 
localized tumors who woutd do well without active therapy. 
Therapeutic options for treatment of localized carcinoma of 
the prostate include extemal beam radiation therapy and radical 
prostatectomy. Khil and Kim discuss the use of ionizing radia-
tion, both extemal beam and interstitial, in the treatment of pros-
tate cancer (pp. 103-107). They emphasize its use in the context 
of primary management of early and locatly advanced prostate 
cancers, as well as in patients who undergo prostatectomy and 
are found to have residual or recurrent local disease. Highly fo-
cused, precision delivery of a curative dose of radiation to the 
prostate is feasible through the use of improved imaging tech-
niques and complex multiple field arrangements. The use of 
three-dimensional extemal beam radiotherapy, as well as a pro-
tocol for concomitant chemotherapy and radiotherapy, is dis-
cussed. 
The Henry Ford Hospital experience with radical prostatec-
tomy in the treatment of localized prostate cancer is presented 
by Telang et al (pp. 108-110). Over 350 patients have been 
treated by radical surgery at Henry Ford Hospital in the past five 
years; Telang and associates analyze the results of the 100 pa-
tients who underwent radical prostatectomy by the nerve-spar-
ing technique. The nerve-sparing technique is discussed in the 
context of whether efforts to spare the neurovascular bundle, in 
an attempt to preserve sexual potency, carry a risk of positive 
surgical margins and incomplete resection of the disease. 
Impotence is an inevitable complication of the treatment of 
carcinoma of the prostate, both by surgical and by radiation 
techniques. Telang and Farah discuss the management of impo-
tence in this setting and present their experience with 50 prostate 
cancer patients who have undergone placement of penile pros-
theses (pp. 111-113), They discuss other therapeutic altema-
tives for patients with impotence resulting from treatment of 
prostatic carcinoma, such as oral pharmacologic therapy, vac-
uum suction and penile constriction devices, and intracaver-
nosal injection therapy. 
Miles and Babiarz review maximal androgen ablation in the 
treatment of advanced prostate cancer (pp, 114-117), Of particu-
lar note is the recent National Cancer Institute study designed to 
evaluate the possibte benefit of combined androgen therapy. 
This study, carried out in patients with previously untreated 
stage D2 prostate cancer, found that combined androgen therapy 
(the use of modalities to suppress both adrenal androgens and 
testicular androgens) significantly increased survival, particu-
larly in those patients with minimal disease and good perfor-
mance status. 
Not discussed in this cohort of papers, but vitally important in 
the diagnosis and management of prostate cancer, is the use of 
TRUS. In conjunction with DRE and PSA determination, TRUS 
is necessary for optimal screening. TRUS also provides accurate 
localization for guided biopsy, gives prostatic dimensions for 
calculation of volume and PSAD, and can assist in establishing 
the stage of localized disease. 
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The rising incidence and mortality of prostate cancer in the 
United States mandate a major clinical, educational, and re-
search commitment to its early diagnosis and appropriate treat-
ment. At the same time, it must be recognized that there is a 
fourteen-fold greater risk of developing prostate cancer than 
there is of dying from it, and many patients may harbor small, 
biologically quiescent or latent lesions which will not progress 
to manifest clinically and should not be treated. In our under-
standable zeal for mass screening, earlier diagnosis, and techno-
logical advances in the treatment of prostate cancer, it is impor-
tant to ask, as Wiltet Whitmore has done, "whether cure is nec-
essary in those in whom it is possible, or whether cure is possi-
ble in those in whom it is necessary." 
Joseph C. Cemy, MD 
Chairman, Department of Urology 
Henry Ford Hospital 
Guest Editor 
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